Clinical trials: Placebo Response
Cognitive Impairment Associated With Schizophrenia
Evoked Responses as Pharmacodynamic Biomarkers in Healthy and Schizophrenic Participants (MK-4334-007)
The primary purpose of this randomized, double-blind, placebo-controlled cross-over study was to record and measure 40 Hz-auditory steady-state response (ASSR) in healthy controls (HC) and participants with mild-to-moderate…
- Trial name
- NCT05136690
- Testing
- Nicotine patch, MK-4334
- Where
- 2 sites in United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Schizophrenia
Efficacy and Safety of a Long Acting Anti-Psychotic Versus Placebo in Patients With Schizophrenia
The purpose of this study is to determine the efficacy (how well the drug works), safety, and side effects of paliperidone palmitate compared to placebo in the treatment of the symptoms of schizophrenia in adults.
- Trial name
- NCT00101634
- Testing
- Paliperidone palmitate
- Volunteers
- 518 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Staphylococcus Aureus
A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)
The purpose of this study is to evaluate the safety and pharmacokinetics (PK) of AZD7760 when given as an intravenous infusion to healthy participants (Phase I) or participants with end-stage kidney disease receiving hemodialysis…
- Trial name
- PEAK (NCT06749457)
- Testing
- AZD7760
- Where
- 40 sites in United States
- Volunteers
- 242 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Lupus Nephritis
Aurinia Renal Response in Active Lupus With Voclosporin
The purpose of this study is to assess the efficacy of voclosporin compared with placebo in achieving renal response after 52 weeks of therapy in subjects with active lupus nephritis.
- Trial name
- AURORA (NCT03021499)
- Testing
- Voclosporin
- Where
- 185 sites in United States, Argentina and 29 more
- Volunteers
- 358 people
- Sponsor
- Aurinia Pharmaceuticals Inc.
Painful Osteoarthritis of the Knee
A Study of the Efficacy and Safety of MEDI7352 in Participants With Painful Osteoarthritis of the Knee
This is a Phase IIb randomised, double-blind, placebo-controlled, dose-response study in participants with painful osteoarthritis (OA) of the knee.
- Trial name
- BESPOKE (NCT04675034)
- Testing
- MEDI7352
- Where
- 41 sites in Denmark, Estonia and 4 more
- Volunteers
- 345 people
- Sponsor
- AstraZeneca
Gastrointestinal Digestion, Healthy
Clinical Trial on Digestive Enzymes: Effects on Post-Meal Response to High-Macronutrient Meals
This study aims to show how digestive enzyme supplements help the body break down fats, proteins, and carbohydrates, especially after eating a high-macronutrient meal.
- Conditions
- Gastrointestinal Digestion, Healthy, Gastrointestinal Wellbeing, Gastrointestinal Supplements
- Trial name
- NCT06949735
- Testing
- Digestive Enzyme Blend
- Where
- Canada
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pancap Pharma Inc.
Gout
Combining Lesinurad With Allopurinol in Inadequate Responders
This study that compare the serum uric acid lowering effects, clinical benefits, and safety of lesinurad in combination with allopurinol to allopurinol alone in subjects with gout who have had an inadequate response to…
- Trial name
- CLEAR 1 (NCT01510158)
- Testing
- Lesinurad, Allopurinol
- Where
- 165 sites in United States
- Volunteers
- 607 people
- Sponsor
- Ardea Biosciences, Inc.
Rheumatoid Arthritis
Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-IR) With Active Rheumatoid Arthritis
The purpose of this study is to determine the efficacy and safety of three different Tregalizumab doses in combination with Methotrexate (MTX) in subjects who have active rheumatoid arthritis and an inadequate response to MTX…
- Trial name
- 986 (NCT01999192)
- Testing
- Tregalizumab
- Where
- 84 sites in United States, Bulgaria and 12 more
- Volunteers
- 321 people
- Sponsor
- Biotest
GERD, Acid Reflux Disease
Validation of Patient-reported Outcomes Measures for the Assessment of Gastroesophageal Reflux Disease (GERD) Symptoms
This research study is being done to gather information about how to do further clinical studies using AZD3355 as an add-on treatment to proton pump inhibitors (PPI).
- Conditions
- GERD, Acid Reflux Disease, Heartburn, Regurgitation
- Trial name
- C27 (NCT00703534)
- Testing
- AZD3355, Gelusil®
- Where
- 84 sites in United States
- Volunteers
- 478 people
- Sponsor
- AstraZeneca
Primary Biliary Cirrhosis
A Study of Efficacy and Safety of Ustekinumab in Patients With Primary Biliary Cirrhosis (PBC) Who Had an Inadequate Response to Ursodeoxycholic Acid
The purpose of this study is to evaluate the efficacy and safety of ustekinumab in patients with primary biliary cirrhosis who had an inadequate response to ursodeoxycholic acid.
- Trial name
- NCT01389973
- Testing
- ustekinumab 90 mg, ustekinumab 45 mg, ustekinumab 180 mg
- Where
- 10 sites in United States, Canada
- Volunteers
- 20 people
- Sponsor
- Janssen Research & Development, LLC
Endometriosis
A Study to Test Whether Study Drug BAY1128688 Brings Pain Relief to Women With Endometriosis and if so to Get a First Idea Which Dose(s) Work Best
Purpose of the study is to test whether study drug BAY1128688 brings relief for pain to women with endometriosis and if so to get a first impression which dose(s) work best.
- Trial name
- AKRENDO1 (NCT03373422)
- Testing
- BAY1128688
- Where
- 68 sites in Austria, Belgium and 11 more
- Volunteers
- 121 people
- Sponsor
- Bayer
Rheumatoid Arthritis, DMARD-naive and Early Disease Patients
A Study of the EP4 Antagonist CR6086 in Combination With Methotrexate, in DMARD-naïve Patients With Early Rheumatoid Arthritis
CR6086 is a new, potent and selective, orally available, small molecule prostaglandin EP4 receptor antagonist, endowed with immunomodulatory properties.
- Trial name
- NCT03163966
- Testing
- CR6086, Methotrexate
- Where
- Czechia
- Volunteers
- 248 people
- Sponsor
- Rottapharm Biotech
Migraine, Common Migraine
A Study of the Efficacy and Safety of Two Doses of Topiramate Compared to Placebo and Propranolol in the Prevention of Migraine
The purpose of this study is to evaluate the safety and efficacy of two doses of topiramate (100 and 200 mg daily) versus placebo and propranolol in the prevention of migraine.
- Conditions
- Migraine, Common Migraine, Classic Migraine, Headache
- Trial name
- NCT00236561
- Testing
- topiramate, propranolol
- Volunteers
- 786 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Major Depressive Disorder With Anxious Distress
A Study of JNJ-61393215 in the Treatment of Depression
The purpose of this study is to evaluate the efficacy of JNJ-61393215 as adjunctive treatment compared to adjunctive placebo, as assessed by the change from baseline to week 6 on a 17-item Hamilton Depression Rating Scale…
- Trial name
- NCT04080752
- Testing
- JNJ-61393215
- Where
- 35 sites in United States, Moldova and 3 more
- Volunteers
- 222 people
- Sponsor
- Janssen Research & Development, LLC
Epilepsy
Effect of Brivaracetam in Photosensitive Epileptic Subjects
to assess the effect of brivaracetam on the photoparoxysmal EEG response in photosensitive epileptic subjects
- Trial name
- NCT00401648
- Testing
- Brivaracetam
- Where
- 5 sites in France, Germany
- Volunteers
- 20 people
- Sponsor
- UCB Pharma
Primary Biliary Cholangitis
Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment.
Study to investigate the efficacy and safety of two doses of K-808 (pemafribate) in subjects with PBC.
- Trial name
- NCT06247735
- Testing
- K-808 (Dose A), K-808 (Dose B)
- Where
- 38 sites in United States, Canada and 1 more
- Volunteers
- 46 people
- Sponsor
- Kowa Research Institute, Inc.
Alzheimer's Disease
Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease
Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose.
- Trial name
- REFLECT-3 (NCT00348140)
- Testing
- Rosiglitazone Extended Release 2mg, Rosiglitazone Extended Release 8mg
- Where
- 194 sites in United States, Australia and 20 more
- Volunteers
- 1,468 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder
MARIGOLD Study: A Study of RO4917523 Versus Placebo as Adjunctive Therapy in Patients With Major Depressive Disorder and an Inadequate Response to Ongoing Antidepressant Therapy
This randomized, double-blind, placebo-controlled, parallel group study will evaluate the safety and efficacy of RO4917523 as adjunctive therapy in patients with major depressive disorder and an inadequate response to ongoing…
- Trial name
- NCT01437657
- Testing
- RO4917523 0.5 mg, RO4917523 1.5 mg
- Where
- 76 sites in United States, Chile and 7 more
- Volunteers
- 319 people
- Sponsor
- Hoffmann-La Roche
Sepsis
A Trial of Heparin in Patients With Severe Sepsis Who Are Undergoing Treatment With Drotrecogin Alfa (Activated)
The purpose of this study is to evaluate the relative efficacy and safety of prophylactic heparin co-administration during drotrecogin alfa (activated) infusion in the treatment of severe sepsis in the adult.
- Trial name
- NCT00049777
- Testing
- Drotrecogin Alfa (Activated), Unfractionated heparin, Low molecular weight heparin
- Where
- Germany
- Volunteers
- 2,000 people
- Sponsor
- Eli Lilly and Company
Type I-Allergy
Dose-Response-Study With a Recombinant Cocktail of Phleum (rPhleum) Allergens
Dose-response trial with a cocktail of recombinant major allergens of Timothy Grass Pollen (Phleum pratense)
- Trial name
- NCT00666341
- Testing
- rPhleum
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Allergopharma GmbH & Co. KG